Michael Grynberg

List of Publications by Year
in descending order

53 papers	1,484 citations	331670 21 h-index	345221 36 g-index
62 all docs	62 docs citations	62 times ranked	1207 citing authors

#	Article	IF	Citations
1	Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. Reproductive BioMedicine Online, 2022, 44, 304-309.	2.4	5
2	Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review. Gynecologic Oncology, 2022, 165, 169-183.	1.4	21
3	Fertility of tomorrow: Are there any restrictions left?. Annales D'Endocrinologie, 2022, , .	1.4	0
4	Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation. Human Reproduction, 2022, 37, 1480-1488.	0.9	3
5	Women utilizing oocyte donation have a decreased live birth rate if they displayed a low progesterone level in a previous hormonal replacement mock cycle. Journal of Assisted Reproduction and Genetics, 2021, 38, 605-612.	2.5	3
6	Live birth rate after use of cryopreserved oocytes or embryos at the time of cancer diagnosis in female survivors: a retrospective study of ten years of experience. Journal of Assisted Reproduction and Genetics, 2021, 38, 1767-1775.	2.5	15
7	Cryopreservation of small numbers of human spermatozoa in a Stripper tip: Report of the first live-birth worldwide. Cryobiology, 2021, 99, 103-105.	0.7	6
8	Could hormonal and follicular rearrangements explain timely menopause in unilaterally oophorectomized women?. Human Reproduction, 2021, 36, 1941-1947.	0.9	3
9	Perspectives on the development and future of oocyte IVM in clinical practice. Journal of Assisted Reproduction and Genetics, 2021, 38, 1265-1280.	2.5	82
10	What is the threshold of mature oocytes to obtain at least one healthy transferable cleavage-stage embryo after preimplantation genetic testing for fragile X syndrome?. Human Reproduction, 2021, 36, 3003-3013.	0.9	4
11	Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy. Frontiers in Oncology, 2021, 11, 701620.	2.8	0
12	Use of the EFI score in endometriosis-associated infertility: A cost-effectiveness study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 253, 296-303.	1.1	14
13	InÂvitro maturation of oocytes for preserving fertility in autoimmune premature ovarian insufficiency. Fertility and Sterility, 2020, 114, 848-853.	1.0	12
14	National survey on the opinions of French specialists in assisted reproductive technologies about social issues impacting the future revision of the French Bioethics laws. Journal of Gynecology Obstetrics and Human Reproduction, 2020, 49, 101902.	1.3	5
15	First follow-up of art pregnancies in the context of the COVID-19 outbreak. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 253, 71-75.	1.1	10
16	Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible. Scientific Reports, 2020, 10, 18555.	3.3	6
17	ESHRE guideline: ovarian stimulation for IVF/ICSIâ€. Human Reproduction Open, 2020, 2020, hoaa009.	5.4	205
18	Does the prognosis after PGT for structural rearrangement differ between female and male translocation carriers?. Reproductive BioMedicine Online, 2020, 40, 684-692.	2.4	13

#	Article	IF	Citations
19	Priming Before In Vitro Maturation Cycles in Cancer Patients Undergoing Urgent Fertility Preservation: a Randomized Controlled Study. Reproductive Sciences, 2020, 27, 2247-2256.	2.5	6
20	In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions. Hematological Oncology, 2020, 38, 560-564.	1.7	4
21	First birth achieved after fertility preservation using vitrification of inÂvitro matured oocytes in a woman with breast cancer. Annals of Oncology, 2020, 31, 541-542.	1.2	27
22	Fertility Preservation in Women. , 2019, , 603-614.		0
23	Anti-MÃ¼llerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811985475.	3.9	20
24	Fertility preservation: should we reconsider the terminology?. Human Reproduction, 2019, 34, 1855-1857.	0.9	5
25	Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria. Frontiers in Endocrinology, 2019, 10, 246.	3.5	28
26	BRCA1/2gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to maturein vitro. Human Reproduction, 2019, 34, 374-379.	0.9	31
27	A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. Journal of Medical Economics, 2019, 22, 108-115.	2.1	7
28	Serum progesterone concentration and live birth rate in frozenâ€“thawed embryo transfers with hormonally prepared endometrium. Reproductive BioMedicine Online, 2019, 38, 472-480.	2.4	91
29	Anti MÃ¼llerian Hormone: More than a biomarker of female reproductive function. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, 19-24.	1.3	51
30	Serum antimÃ¼llerian hormone is associated with the number of oocytes matured inÂvitro and with primordial follicle density in candidates for fertility preservation. Fertility and Sterility, 2019, 111, 357-362.	1.0	34
31	A comparison of the effects of three luteal phase support protocols with estrogen on in vitro fertilization-embryo transfer outcomes in patients on a GnRH antagonist protocol. Jornal Brasileiro De Reproducao Assistida, 2019, 23, 239-245.	0.7	9
32	Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkinâ€™s lymphoma when compared with breast cancer candidates for fertility preservation. Journal of Assisted Reproduction and Genetics, 2018, 35, 91-97.	2.5	12
33	Oocyte vitrification for preserving fertility in patients with endometriosis: first observational cohort studyâ€¦ and many unresolved questions. Letter to the Editor. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 220, 140-141.	1.1	32
34	Comparison of GnRH agonist and hCG for priming in vitro maturation cycles in cancer patients undergoing urgent fertility preservation. PLoS ONE, 2018, 13, e0208576.	2.5	8
35	Medical techniques of fertility preservation in the male and female. Journal of Visceral Surgery, 2018, 155, S3-S9.	0.8	4
36	Are age and anti-MÃ¼llerian hormone good predictors of ovarian reserve and response in women undergoing IVF?. Jornal Brasileiro De Reproducao Assistida, 2018, 22, 215-220.	0.7	23

#	Article	IF	Citations
37	Letter in reply to â€œFertility preservation before an ABVD protocol: no new evidence to support changing the recommendationsâ€• Future Oncology, 2017, 13, 591-592.	2.4	1
38	PreservaciÃ³n de la fertilidad femenina. EMC - GinecologÃa-Obstetricia, 2017, 53, 1-15.	0.0	1
39	Should we consider day-2 and day-3 embryo morphology before day-5 transfer when blastocysts reach a similar good quality?. Reproductive BioMedicine Online, 2017, 35, 521-528.	2.4	27
40	Age as A Predictor of Embryo Quality Regardless of The Quantitative Ovarian Response. International Journal of Fertility & Sterility, 2017, 11, 40-46.	0.2	23
41	What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation afterin vitromaturation?. Human Reproduction, 2016, 31, 1493-1500.	0.9	44
42	Fertility preservation in Turner syndrome. Fertility and Sterility, 2016, 105, 13-19.	1.0	77
43	Similarin vitromaturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Human Reproduction, 2016, 31, 623-629.	0.9	74
44	The past, present and future of fertility preservation in cancer patients. Future Oncology, 2015, 11, 2667-2680.	2.4	9
45	Is it acceptable to destroy or include human embryos before day 5 in research programmes?. Reproductive BioMedicine Online, 2014, 28, 522-529.	2.4	13
46	InÂvitro maturation of oocytes: uncommon indications. Fertility and Sterility, 2013, 99, 1182-1188.	1.0	47
47	First Birth Achieved After In Vitro Maturation of Oocytes From a Woman Endowed With Multiple Antral Follicles Unresponsive to Follicle-stimulating Hormone. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4493-4498.	3.6	38
48	New trends in female fertility preservation:in vitromaturation of oocytes. Future Oncology, 2012, 8, 1567-1573.	2.4	42
49	Antral follicle responsiveness to follicle-stimulating hormone administration assessed by the Follicular Output RaTe (FORT) may predict in vitro fertilization-embryo transfer outcome. Human Reproduction, 2012, 27, 1066-1072.	0.9	80
50	Ovarian tissue and follicle transplantation as an option for fertility preservation. Fertility and Sterility, 2012, 97, 1260-1268.	1.0	71
51	Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation. Human Reproduction, 2011, 26, 671-677.	0.9	94
52	Early follicle development alters the relationship between antral follicle counts and inhibin B and follicle-stimulating hormone levels on cycle day 3. Fertility and Sterility, 2010, 93, 894-899.	1.0	5
53	Early follicle development during the luteal-follicular transition affects the predictability of serum follicle-stimulating hormone but not antimÃ¼llerian hormone levels on cycle day 3. Fertility and Sterility, 2010, 94, 1827-1831.	1.0	4